Proliferative retinopathy
Proliferative retinopathy is characterized by the formation of new vessels which arise from the optic disc or the retinal periphery. New vessels grow in response to vascular occlusion, i.e. retinal ischaemia. Even in their earliest form, the new vessels are associated with a fine, transparent, fibrous-tissue covering, which increases and becomes more marked with the evolution of the disease. Early new vessels arise most commonly from the major veins and lie initially on the surface of the retina. The fibrovascular buds, as they grow, break through the internal limiting membrane of the retina and form adhesions with the cortical vitreous, giving rise to dense epiretinal membranes.
It is essential to realize that until this stage proliferative lesions, though present, do not give rise to visual symptoms. It is the further evolution and complication of these lesions which lead to visual loss. As the fibrous tissue contracts, it pulls on the vessels it is attached to, giving rise to subhyaloid, retrovitreal or vitreous haemorrhage, the commonest early complication of proliferative retinopathy. While the first haemorrhage usually absorbs spontaneously (unless it breaks into the vitreous gel), it does present a serious prognostic feature. Caird et al. (1968) found that one-third of all untreated patients were blind in both eyes within 3 years of their first vitreous haemorrhage.
The other complications of proliferative diabetic retinopathy are associated with detachment of the posterior vitreous, to which the epiretinal membrane adheres, resulting in anterior-posterior vitreoretinal traction, which tends to pull the retina into the centre of the globe causing retinal detachment.
In some patients, growth of new vessels is not restricted to the retina, but may arise from the iris and the angle of the anterior chamber, where they block the outflow channels and result in the painful blindness caused by thrombotic glaucoma.
Thus, it is not the new vessels themselves, but the resulting complications of haemorrhage, traction, detachment and blockage of anterior segment outflow which lead to blindness in untreated proliferative retinopathy.
Diabetic maculopathy
Diabetic maculopathy is characterized by features of background retinopathy associated with macular oedema, the oedema leading to visual loss.
The features of background retinopathy include microaneurysms, blot-and-dot haemorrhages and scattered hard exudates. These lesions by themselves do not cause visual loss. However, in maculopathy there is the addition of oedema fluid accumulation and the deposition of hard exudate plaques at the fovea. Hard exudates, like oedema, are the result of abnormal permeability of the retinal vessels, allowing exudation of fluid from the vessels into the retina. The hyperpermeability of the retinal microvasculature is usually most marked in the macular area. In diabetic maculopathy therefore, while central, reading vision is lost, peripheral navigational vision is often maintained. Only when proliferative retinopathy supervenes is there complete blindness.
Clinically, diabetic maculopathy can be subdivided into exudative, oedematous and ischaemic types. Of these, the exudative ones, characterized by hard exudates, are most easy to diagnose and have the best prognosis. This is particularly so when there are either scattered hard exudates or hard exudate rings (circinate retinopathy) well away from the macula and advancing gradually towards it. Increasing numbers of haemorrhages associated with the hard exudates suggest developing ischaemia, and a worse prognosis. In the oedematous maculopathy, diffuse oedema may arise fom leakage of all capillaries, or cystoid macular oedema may affect the fovea and perifoveal region only. Both these forms are associated with severe visual loss. Ischaemic maculopathy also carries poor visual prognosis. It is characterized by perifoveal ischaemia associated with large areas of peripheral nonperfusion. Patients with these lesions are in danger of new vessel development (Whitelocke et al. 1979) .
Visual loss in diabetic maculopathy is thus caused by accumulation of oedema fluid, hard exudate plaques and added ischaemia.
Photocoagulation for diabetic retinopathy Photocoagulation is the application of light energy to the retina, which when absorbedmostly by the pigment epitheliumis converted into heat. The resulting burn destroys retinal tissue and occludes vessels. Photocoagulation is therefore essentially a destructive process which nevertheless has beneficial effects in diabetic retinopathy.
The rationale of photocoagulation is twofold: (1) It can be used to occlude or destroy abnormal vessels or microaneurysms and thusstop leakage (or haemorrhage). This is a common usage in exudative maculopathy; occasionally it is used for new vessels which do not respond to other methods of treatment.
(2) It is most commonly used to destroy large areas of peripheral avascular retina, which is thought to be the origin of the vasoproliferative factor, responsible for new vessel formation. This form of treatment is *known as panretinal photocoagulation (PRP), peripheral scatter treatment or pattern bombing. It is the type of treatment most commonly used for proliferative retinopathy.
The equipment used for photocoagulation is now almost exclusively the argon laser, the green light of which is absorbed by both the pigment epithelium and haemoglobin, so that occlusion of forward new vessels is possible. The laser beam is shone into the eye through a slit lamp, giving the operator binocular vision and relative comfort. The high-intensity laser light is applied in bursts of 0.1-0.2 seconds. Complete immobilization of the patient's eye is therefore not usually necessary and the light is applied through a contact lens. The light beam can be varied from as small as 50 p to 1000 ,u and allows work near the macula. Because of the highly focused light, the intensity drops off rapidly; as a result the damage caused is usually localized, and only with very high intensities is there destruction of the full thickness of the retina.
The white light of the xenon arc was the first method of photocoagulation. It produces larger burns, 200 p or larger in diameter, it is absorbed by pigment epithelium and produces intense burns of the full thickness of the retina. It requires immobilization of the eye by retrobulbar anaesthesia. It is more comfortable for the patient who has to lie down and cannot see or feel anything, but back-breaking for the ophthalmologist who has to bend over the patient to apply the treatment. Because of the large, 'full-thickness' burns, complications of treatment are more common. However, in experienced hands both instruments are useful for the treatment of both proliferative retinopathy and diabetic maculopathy.
Photocoagulation for proliferative retinopathy
Proliferative retinopathy represents a serious threat to the sight of insulin-dependent diabetics (IDD) in early adult life; it therefore attracts much attention. It is patients with this condition in whom photocoagulation is and has been used most extensively. Three early studies which treated one eye only, usually the worst one, arrived at inconclusive results: Okun & Johnston (1969) and Beetham et al. (1970) both felt that treatment was beneficial, while Irvine & Norton (1971) were less sure of their results.
The conclusive results came from two large multicentre randomized controlled clinical studies, in which one eye chosen by a random procedure was treated while the other remained as untreated control. The largest and best of these studiesthe American Multicentre Studywas carried out by the Diabetic Retinopathy Study Research Group (DRS). Due largely to the dedicated work of Matthew Davis and the generous funding of the National Eye Institute, over 1700 patients were recruited into the study (DRS 1976 (DRS , 1981 . Both xenon and argon treatments were used, and the treatment method strictly controlled. Major visual loss to 3/60 or worse was taken as the end point. The results were striking, especially in those patients in whom new vessels arose from the optic disc, with or without new vessels in the retinal periphery, with or without previous or present vitreous haemorrhage. The difference between treated and control eye was highly statistically significant after 18 months with a Z value of 3-7 (a Z value of 1.96 approximates to P < 0.05). Other 'high-risk' eyes also responded dramatically. These included forward peripheral vessels and eyes with previous vitreous haemorrhage. The difference was marginal when uncomplicated peripheral new vessels only were present, and there was no beneficial effect from treatment in those who only had severe background retinopathy (DRS 1976) . The dramatic benefits resulted in a change in treatment protocol after 2 years, so that eyes hitherto untreated could be treated provided they still had treatable lesions. The 5-year results showed that severe visual loss (approximating to 'legal blindness' in the UK) was 15% in treated eyes, but 35% in control eyesa highly significant difference (Rand 1982) . The control group included those treated after the 2-year change of protocol, and therefore if treatment at that time had not saved many eyes, the difference would undoubtedly have been much greater.
The British Multicentre Study Group only used xenon treatment, and the number of patients studied was smaller (BMS 1977 (BMS , 1984 . However, in this study the two eyes were always similarly affected, thus allowing a paired comparison between treated and untreated eyes. As in the American study, treated eyes fared better than untreated ones. When all eyes were considered, the mean deterioration in visual acuity in treated eyes was only one line on the Snellen Chart, while it was 2 lines in control eyes (P < 0.001). When only eyes with new vessels on the disc were considered the difference was larger, with the control eyes deteriorating by more than 3 lines (P<0.001) (BMS 1984) . There were significantly fewer treated eyes which lost vision to blindness than untreated ones (Table 1) . The British study did not specify the number of burns to be applied, nor did it insist on PRP or focal treatment, hoping that the results would indicate optimum treatment. The results did in fact show that those who had less extensive treatment were more likely to lose vision subsequently if they had disc vessels on entry into the study, and develop new vessels on the disc if they did not already have them when first seen. Extensive PRP was most effective in the treatment of new vessels arising from the disc. Photocoagulation is useful in maintaining vision in all patients with proliferative retinopathy, including those with florid diabetic retinopathy (Figure 1 ) who previously were thought to respond to pituitary ablation only (Kohner et al. 1976) . It is also effective in the treatment of pregnant patients (Hercules et al. 1980 ). Effective treatment before or during pregnancy commonly prevents recurrence of new vessels in any subsequent pregnancy.
As a result of the benefit demonstrated by these randomized controlled studies, photocoagulation has been used by many centres as a treatment for proliferative retinopathy. There is now little doubt that the earlier the treatment, the more likely it is to be effective and that, for optimum results, adequate treatment is essential: a PRP of less than 2000 burns of 500 It spot size is hardly ever effective for disc new vessels and occasionally as many as 5000-6000 burns are required. PRP should be used for peripheral vessels also, since otherwise there remains a risk that disc new vessels will develop.
Diabetic maculopathy
Diabetic maculopathy is primarily a disease of the middle-aged and elderly and for this reason attracts less attention than proliferative retinopathy. If untreated, the visual loss is gradual and patients often attend for treatment late, when the visual loss is irreversible. In spite of this, most studies of photocoagulation in diabetic maculopathy have shown a beneficial effect, though the results have never been as dramatic as those in proliferative retinopathy.
The largest of the studies is the British Multicentre Study (Townsend et al. 1980 , BMS 1983 in which 99 patients with two similarly affected eyes had one eye (chosen by random procedure) treated by the xenon arc photocoagulator, the other acting as the untreated control. The 5-year results show that treatment by photocoagulation confers distinct advantages. The mean visual acuity deteriorated by less than one line in treated eyes, but by more than 2 lines in control eyes (P < 0.01). The difference in deterioration was greatest in those who had initially good vision: 6/6-6/9. In these, out of 20 treated eyes, only one became blind (6/60 or worse vision for 2 successive yearly visits), while 10, i.e. 50%, of the control eyes lost this degree of vision. Those with initially poor vision, 6/36 or worse, did not benefit from treatment, though even in these there was a trend favouring treatment and larger studies may show benefit even in this group. Significantly fewer treated than control eyes became blind (Table 2) . These studies were carried out before clinical subdivision of diabetic maculopathy became available (Kohner 1978 , Whitelocke et al. 1979 ; indeed, these studies encouraged the subdivision of maculopathy. From later reports it appears likely that the more marked benefitsseen in those with good visionoccur in those with hard exudate rings away from the fovea, or only just affecting macular vision. In 1973 it had already been noted by Patz and co-workers, when using the argon laser in a randomized controlled study, that on the whole treated eyes fared better than untreated ones, but that those with perifoveal ischaemia (ischaemic maculopathy) did not respond to photocoagulation. Whitelocke et al. (1979) , however, considered that these patients should nevertheless be treated, not only treating lesions in the macular region, but also the ischaemic retinal periphery to avoid development of new vessels. When peripheral PRP was not applied, over one-third of these patients developed new vessels within two years, threatening complete blindness. In diffusely oedematous maculopathy, treatment is rarely effective as it is in those with cystoid oedema. Nevertheless, when visual loss is not profound, treatment by a perifoveal grid is sometimes successful in maintaining vision.
The method of treatment in maculopathy is more controversial than in proliferative retinopathy. When the lesions are rings of hard exudates, destroying the microvascular lesions in the centre of the rings (provided they are not at the fovea) is clearly of benefit: it causes disappearance of hard exudates and reduction of oedema. When there are scattered hard exudates, direct treatment of microvascular lesions can be beneficial; while in the oedematous maculopathies grids are now commonly used, though not with well established beneficial effect.
It can be stated with confidence that diabetic maculopathy, especially in its early stages, does respond to photocoagulation, and treatment will often prevent blindness in these patients.
Screening for diabetic retinopathy
The finding that early treatment of diabetic retinopathy can prevent blindness necessitates detection of patients in need of treatment. This is particularly important in proliferative retinopathy, which is symptom-free until the appearance of complications. How can patients needing treatment be found, and how should one deal with patients when they have retinopathy? Clearly a screening programme has to be established.
The responsibility for screening for retinopathy rests with the doctor in charge of the particular patient, be it a hospital diabetic clinic or the general practitioner. No doctor who cannot use an ophthalmoscope should be responsible for the care of diabetic patients. If all patients are screened regularly, extra time is required. Does it need extra manpower? In the diabetic clinic, visual acuity can be checked by a nurse, with the patient's glasses or with a pinhole (which eliminates many refractive problems). She can also put drops into the patient's eye, so that by the time the doctor sees the patient, the eyes can be examined. The examination rarely takes more than 3-4 minutes. If this time is not available, the whole organization of the clinic may need rethinking: after all, the aim in controlling diabetes is to prevent acute and chronic complications. Physicians will have to learn to recognize lesions, and initially this will mean extra time spent learning with an ophthalmologist. The Glasgow experience shows that, when trained, physicians are nearly as good as ophthalmologists in recognizing diabetic retinopathy (Scobie et al. 1981) .
The problem in general practice is greater because few GPs have enough diabetic patients to be sufficiently familiar with early detection of the different lesions. The help of opticianstrained in looking at the retinacan be sought, but a close cooperation between GPs, opticians and ophthalmologists is essential.
Ophthalmologists are too few at present to undertake screening of the whole diabetic population, but most larger diabetic clinics can get help in the form of experienced clinical assistants.
If it were to be considered negligent not to look regularly at the fundus of diabetic patients, or if doctors were paid a fee for ophthalmoscopy, much blindness in the UK would be prevented.
Ideally, all diabetic patients should have their eyes checked yearly. As this may not be possible immediately, patients 'at risk' should be checked first. These include newly diagnosed NIDD patients, IDDs at diagnosis and after 5 years' duration of diabetes, patients who are pregnant or go on the contraceptive pill, and any patient who is admitted with a diabetes-related illness in its widest sense (including vascular surgery and myocardial infarct). NIDDs are more commonly at risk from maculopathy, and in this condition visual loss is early. Patients who often attribute their deteriorating vision to 'old age' have to understand that poor vision is not normal at any age. Visual acuity testing in these patients is most useful. Ideally they also should have their eyes seen yearly, but provided there is no retinopathy at diagnosis and in the absence of visual deterioration, 2-3 yearly fundus examination will probably suffice.
Screening should include checking of visual acuity and examination of the fundi through dilated pupils, preferably in a darkened room. Many of the lesions, especially new vessels, start in the peripheral retina and are difficult to diagnose in their early stages, and if the pupil reacts to light they will be missed.
The lesions looked for are those which indicate the presence or imminent development of sight-threatening retinopathy.
(1) The presence of even 2-3 microaneurysms and haemorrhages or few scattered exudates indicates that retinopathy is present. Since the advance of this is variable and cannot yet be predicted, patients with such lesions should have their eyes checked again after 6 months. If the retinopathy has not advanced, yearly examination is sufficient in most instances. However, if it has advanced significantly, more frequent examination is indicated. Special vigilance is necessary in those who already have retinopathy when diabetes is diagnosed: in these patients lesions often advance very rapidly.
(2) Preproliferative retinopathy is a retinopathy in which there is widespread ischaemia, but no new vessels are seen. The features which indicate ischaemia are multiple cotton-wool spots, clusters or large blot haemorrhages, venous loops or beading, dilated abnormal capillaries, known as intraretinal microvascular abnormalities, and white lines replacing major vessels. When such lesions are seen, the patient should be referred to an ophthalmologist specializing in treating diabetic retinopathy; in most instances, new vessels develop within 6-12 months.
(3) Proliferative retinopathy of any sort should be referred to a treating ophthalmologist without delay. If the new vessels arise from the disc, the ophthalmic appointment is urgent. (4) Maculopathy patients with hard exudate rings should also be referred to an ophthalmologist, for although treatment is not urgent it is best done early. Once visual loss is present an ophthalmologist should see the patient and, if possible, treat.
Treatment availability
Lasers are available in large numbers through the country. Even if not available, local charities will often supply the money for their purchase. A much more serious problem is the lack of skilled manpower. Unfortunately, senior registrars in ophthalmology can be appointed as consultants without ever having treated diabetic retinopathy. The Royal College of Surgeons has hitherto not taken seriously the importance of laser treatment. Even if a doctor has a laser, there is no compulsion to learn its proper use. The result is that many patients lose vision in spite of treatment, because the treatment is completely inadequate.
It is not necessary for each district general hospital to have a laser and treat diabetic retinopathy. Treatment is most effective in centres where physicians and ophthalmologists are interested in diabetic retinopathy and work as a team. A major problem is that patients are sent by physicians and GPs to the local hospital opthalmology clinic (where there may be a 3-6 month waiting list) from where they are secondarily referred to a treatment centre. If there was initially a delay between optician and GP, the overall delay may be as much as 9-12 months. By this time, many patients have lost their sight and are untreatable. Diabetic treatment centres should accept patients directly from opticians, GPs or hospital physicians so as to reduce the number of hospital visits and the waiting time for treatment. (It would also be cost effective.)
Treatment should be carried out by someone trained in ophthalmology. It is hard, often tedious, though usually very rewarding work, which can be done effectively by trained junior staff. The consultant is responsible for training staff and supervising the treatment, and also for training those who do the screening.
Well over 1000 patients a year in the UK become blind because of diabetic retinopathy. This figure could be reduced significantly.
